Condition

Primary Central Nervous System Lymphoma clinical trials and research

• 19Clinical trials
• 4Countries

Newest Primary Central Nervous System Lymphoma clinical trials

All recruiting trials (19)

• Rapid CSF ctDNA Test and Treatment Monitoring for Primary CNS Lymphoma

  This study tests whether CSF circulating tumor DNA can quickly diagnose primary CNS lymphoma and monitor response to treatment in adults.

  Recruiting Beijing Tiantan Hospital · Beijing, Beijing Municipality · NCT07851363

• Testing a four-drug regimen (methotrexate, rituximab, sintilimab, pirtobrutinib) versus investigator-selected care for newly diagnosed PCNSL

  This trial will try a combination of methotrexate, rituximab, sintilimab and pirtobrutinib as first treatment for adults with newly diagnosed primary central nervous system lymphoma to see if it increases complete remissions and is safe compared with standard doctor-selected treatments.

  Recruiting at 3 sites Phase 2 Tongji Hospital · Xiamen, Fujian and 3 other locations · NCT07350850

• Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL

  In this study, adults with newly diagnosed primary CNS lymphoma try different induction regimens to see which one works best before consolidation therapy.

  Recruiting at 9 sites Phase 2/3 Huashan Hospital · Beijing and 14 other locations · NCT07185373

• Epcoritamab plus ibrutinib for central nervous system lymphoma

  This trial tests whether combining epcoritamab and ibrutinib is safe and tolerable for adults with relapsed or refractory primary or secondary central nervous system lymphoma.

  Recruiting at 8 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 7 other locations · NCT07082868

• Tirabrutinib maintenance therapy for patients with primary CNS lymphoma in remission

  This study is testing if taking tirabrutinib every day can help people with primary CNS lymphoma stay in remission longer after their initial treatment.

  Recruiting Phase 2 Kyorin University · Tokyo · NCT06940791

• Glofitamab after obinutuzumab pre-treatment for central nervous system lymphoma

  This trial will test if giving glofitamab after a short obinutuzumab pre-treatment is safe and helpful for adults with primary or secondary central nervous system lymphoma.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT06922604

• Using RMTT regimen as first-line therapy for primary central nervous system lymphoma

  This study is testing if a new combination treatment called RMTT can help people with primary central nervous system lymphoma who haven't had treatment before.

  Recruiting Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT06832267

• High-dose chemotherapy with stem cell transplant versus standard treatment for elderly patients with brain lymphoma

  This study is testing whether a stronger chemotherapy treatment with stem cell transplant can help older patients with brain lymphoma live longer and feel better compared to the usual treatment.

  Recruiting at 21 sites Phase 3 University Hospital Freiburg · Freiburg im Breisgau, Baden-Wurttemberg and 34 other locations · NCT06830421

• Q702 to treat blood cancers

  This Phase 1 trial will test whether the oral drug Q702 is safe, tolerable, and what dose works best for adults with certain blood cancers who have failed or are not eligible for standard treatments.

  Recruiting at 2 sites Phase 1 Mayo Clinic · Scottsdale, Arizona and 1 other locations · NCT06712810

• Combining Pembrolizumab with chemotherapy for newly diagnosed brain lymphoma

  This study is testing if combining Pembrolizumab with chemotherapy can help people who have just been diagnosed with brain lymphoma feel better and improve their treatment outcomes.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06475235

• Using obinutuzumab to maintain response in patients with central nervous system lymphoma

  This study is testing if a medication called obinutuzumab can help people with central nervous system lymphoma stay in remission longer after their initial treatment.

  Recruiting at 6 sites Phase 2 Providence Health & Services · New York, New York and 6 other locations · NCT06175000

• Combining zanubrutinib and pemetrexed for treating relapsed or refractory CNS lymphomas

  This study is testing if combining two medications, zanubrutinib and pemetrexed, can help people with relapsed or stubborn central nervous system lymphomas feel better and live longer.

  Recruiting Phase 2 Baptist Health South Florida · Miami, Florida · NCT05681195

• Combination treatment for newly diagnosed primary central nervous system lymphoma

  This study is testing a new combination of treatments for people with newly diagnosed primary central nervous system lymphoma to see if it helps them respond better and live longer.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hanzhou, Zhejiang · NCT05600660

• Combination treatment of Tafasitamab and Lenalidomide for relapsed CNS lymphoma

  This study is testing a combination of two drugs, Tafasitamab and Lenalidomide, to see if they can help people with relapsed central nervous system lymphoma feel better and improve their treatment outcomes.

  Recruiting Phase 1/2 University of California, San Francisco · San Francisco, California · NCT05351593

• Testing Paxalisib for recurrent primary central nervous system lymphoma

  This study is testing a new drug called Paxalisib to see if it can help people with recurrent primary central nervous system lymphoma feel better and manage their condition.

  Recruiting Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT04906096

• Combination treatment for primary central nervous system lymphoma

  This study is testing a new combination of medications to see if it can help people with primary central nervous system lymphoma feel better and improve their treatment outcomes.

  Recruiting Phase 2 Henan Cancer Hospital · Zhengzhou, Henan · NCT04737889

• Combination therapy for recurrent primary central nervous system lymphoma

  This study is testing a new combination of three medications to see if it can help people with recurrent primary central nervous system lymphoma feel better after their previous treatments didn't work.

  Recruiting at 3 sites Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts and 3 other locations · NCT04421560

• Treatment for elderly patients with primary central nervous system lymphoma

  This study is testing a new treatment for older patients with primary central nervous system lymphoma to see if it helps them live longer and feel better without using radiation right away.

  Recruiting Phase 2/3 Navy General Hospital, Beijing · Beijing, Beijing Municipality · NCT02836158

• Treatment for primary central nervous system lymphoma using R-IDARAM and intrathecal chemotherapy

  This study tests a new treatment combining R-IDARAM and intrathecal chemotherapy to see if it helps people with primary central nervous system lymphoma feel better and live longer.

  Recruiting Phase 2/3 Navy General Hospital, Beijing · Beijing, Beijing Municipality · NCT02657785

Related topics

Quick answers

How many Primary Central Nervous System Lymphoma clinical trials are recruiting right now?

19, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 4 countries. The most sites are in United States (9 trials), China (8 trials), Japan (1 trial), Germany (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 7, Phase 1: 4, Phase 2/3: 3, Phase 1/2: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →